US20170354734A1 - Salicylic acid gel - Google Patents
Salicylic acid gel Download PDFInfo
- Publication number
- US20170354734A1 US20170354734A1 US15/688,560 US201715688560A US2017354734A1 US 20170354734 A1 US20170354734 A1 US 20170354734A1 US 201715688560 A US201715688560 A US 201715688560A US 2017354734 A1 US2017354734 A1 US 2017354734A1
- Authority
- US
- United States
- Prior art keywords
- salicylic acid
- gel
- solvent
- total weight
- acid gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- YGSDEFSMJLZEOE-UHFFFAOYSA-N O=C(O)C1=C(O)C=CC=C1 Chemical compound O=C(O)C1=C(O)C=CC=C1 YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/41—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/006—Antidandruff preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
Definitions
- the invention relates to a concentrated gel of salicylic acid, and products produced therefrom.
- Salicylic acid also known as 2-hydroxybenzenecarboxylic acid, is a monohydroxybenzoic acid. Its salts and esters are known as salicylates. Salicylic acid has the formula:
- Salicylic acid is also known for providing pain relief when applied as a liniment, for example
- Salicylic acid is used in many skin-care products. For example, salicylic acid is well known for its use in anti-acne treatments. In addition to the treatment of acne, salicylic acid is also used in products for treatment of psoriasis, calluses, corns, keratosis pilaris, and warts. It works as a keratolytic, bacteriocide and comedolytic agent. Salicylic acid is also used in shampoos for treatment of dandruff and as a chemical exfoliant.
- Salicylic acid can cause burns if applied in high concentrations. Typically, over-the-counter limits are 2% for topical treatments (that remain on the skin) and 3% for cleansers or shampoo (products that are washed off.) Higher concentrations (e.g. up to 40 wt %) may be used for wart removal but should be applied cautiously and only to the wart and not the surrounding skin.
- Salicylic acid is poorly soluble in water. It is therefore difficult to prepare solutions of salicylic acid that remain precipitate-free.
- the present invention is directed to a concentrated salicylic acid gel comprising salicylic acid and a stabilizer compound, wherein the salicylic acid comprises at least 30 wt % of the total weight of the gel.
- the present invention is further directed to a dilute salicylic acid solution comprising the concentrated salicylic acid gel and a solvent wherein the concentration of the salicylic acid in the solution is 25 wt % or less.
- the present invention is further directed to products prepared with the concentrated salicylic acid gel or with dilute solution of the gel in water.
- the salicylic acid gel is combined with ingredients to form a body or hand lotion. In another aspect the salicylic acid gel is combined with ingredients to form an anti-dandruff shampoo. In yet another aspect the salicylic acid gel is combined with ingredients to form wart medication. In yet another aspect the salicylic acid gel is combined with ingredients to form an anti-acne medication.
- aspects of the invention are directed to a concentrated gel of salicylic acid and at least one stabilizer compound selected from nitrogen compounds.
- the concentrated gel comprises at least 30 wt % salicylic acid, for example 30 wt % to 60 wt %, or 40 to 55 wt % salicylic acid, based on total weight of the gel.
- the concentrated gel comprises the stabilizer compound in an amount of 40 to 70 wt %, or 45 to 60 wt %, which is an amount effective to provide stability to the salicylic acid in the gel.
- the concentrated salicylic acid gel is formed by mixing salicylic acid with the stabilizer compound until the salicylic acid is dissolved in the stabilizer compound. No water or solvent such as ethanol is included in the gel. There are only two components that form the gel: the stabilizer compound (complexing agent) and the salicylic acid.
- the mixing of the salicylic acid and the stabilizer compound may be done at room temperature. Alternatively the mixing may occur at an elevated temperature such as up to 50° C. Generally mixing takes about 30 to 120 minutes.
- the concentrated gel may then be stored for future use. Since the gel contains very concentrated salicylic acid, less storage space is required than dilute solutions of salicylic acid.
- the stabilizer compound may be any suitable nitrogen compound that stabilizes the salicylic acid in the concentrated gel.
- Nitrogen compounds useful to form the highly concentrated salicylic gel include, but not limited to, alkoxylated amides, alkoxylated amines, alkyl-substituted amino acids, alkylamido alkylamines, amides, amine oxides, amines, and betaines. Ideally, a clear product should be produced.
- the nitrogen compound is cocamidopropyl dimethylamine.
- the cocamidopropyl dimethylamine is particularly suitable for high concentrations of salicylic acid. When diluted in water, the resulting solution is stable and clear.
- the concentrated gel can be diluted to any suitable level for use. Dilution of the salicylic acid gel may occur by the addition of water, a short chain alcohol such as ethanol and isopropanol, or any combination thereof. Upon dilution, the salicylic acid forms a clear, stable solution in the water or alcohols—that is, the salicylic acid does not precipitate out.
- a short chain alcohol such as ethanol and isopropanol
- the pH of the dilute system is generally less than 5, such as 2 to 5, 2.5 to 4.5, typically 3 to 4.
- the dilute system For topical purposes, the dilute system must pass the USP Monograph for a Salicylic Gel which includes an assay for salicylic acid.
- the diluted product may be combined with other suitable ingredients to form the final products such as creams, lotions, make-ups, toners, astringents, skin cleansing compositions, shampoos, and conditioners. These compositions contain about 0.1-40 wt % of salicylic acid. The amount of salicylic acid in the final product depends on the intended purpose of the product.
- Cream C is typically contain about 10-90 wt % water and 10-90 wt % oil.
- Creams may also contain humectants, emollients, surfactants, emulsifiers, preservatives and fragrances. Creams would generally contain from 0.1 to 5 wt % salicylic acid.
- L4a-t[99s typically contain 20-80 wt % oil and 10-80 wt % water in an emulsion form.
- lotions may contain humectants, emollients, surfactants, fragrances, preservatives and so forth.
- Creams would generally contain from 0.2 to 5 wt % salicylic acidke-ups typically contain about 5-70 wt % oil, 10-95 wt % water, and about 5-40 wt % pigment.
- the makeup may contain surfactants, silicones as part of the oil phase, humectants, emollients, preservatives, fragrances, etc. Make-up would generally contain from 0.1 to 3 wt % salicylic acid.
- Anti-dandruff shampoos typically contain 1-40 wt % of a cleansing surfactant and 1090 wt % water.
- the shampoo may also contain any one of ingredients such as surfactants, colorants, preservatives, fragrance, emulsifiers, viscosity adjusters, and conditioning agents.
- Anti-dandruff shampoos would generally contain from 0.18 to 3 wt % salicylic acid.
- Hair conditioners typically contain include 10-95 wt % water, 0.5-30 wt % conditioning ingredients such as quaternary ammonium compounds or amphoteric polymers, proteins, etc., and 1-40% surfactants. Hair conditioners may also contain volatile or nonvolatile silicones. Hair conditioners would generally contain from 0.1 to 4 wt % salicylic acid.
- Toners typically contain about 0-85 wt % alcohol, 0.01-5 wt % surfactant, and 0.1-5 wt % humectants, 0.1-85% water.
- the salicylic acid may also be used in ointments, gels, or solutions.
- Suitable ointments are hydrophilic ointments (USP) or petroleum.
- the amount of salicylic acid present in the final product depends on the product.
- acne treatment products generally contain 0.5 to 2 wt % salicylic acid
- dandruff and seborrheic dermatitis and psoriasis treatment products generally contain 3 wt % salicylic acid
- wart treatments generally contain up to 40 wt % salicylic acid, typically 5 wt % to 40 wt % or 17 wt % to 25 wt %.
- the concentrated gel was diluted to 2 wt % active salicylic acid in water and separately in ethanol.
- the resulting solutions were clear and colorless. No precipitate was formed either in water or in ethanol.
- the pH of the water solution was approximately 3.2.
- the gel was also diluted to 25 wt % active salicylic acid in water.
- the resulting solution was a slightly viscous, yellow, clear solution. No precipitate was formed.
- a physical accelerated stability test was run on this prototype consisting of samples be held at 50° C. for two weeks and another sample run through five freeze/thaw cycles. Under both of these conditions there were no physical changes to the product include pH, viscosity, color and appearance.
- a lotion was prepared with 5% of the gel of example 1 in 91% water with 4% Egel 305 [Polyacrylamide (&) C12-13 isoparaffin (&) Laureth-7].
- the result was a white lotion that would be applicable for an anti-acne product. It underwent the same accelerated stability testing as mentioned above (50° C. for 2 weeks and 5 freeze/thaw cycles); there were no significant physical changes to the product during the stability testing.
- An anti-dandruff shampoo was prepared containing 3 wt % salicylic acid.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A concentrated salicylic acid gel comprising salicylic acid and a stabilizer compound, wherein the salicylic acid comprises at least 30 wt % of the total weight of the gel.
Description
- This application is a continuation of U.S. application Ser. No. 14/454,886, filed Aug. 8, 2014, which application is a continuation of U.S. application Ser. No. 13/789,780, filed Mar. 8, 2013, (now U.S. Pat. No. 8,828,979, issued Sep. 9, 2014), which claims priority to U.S. Provisional Application Ser. No. 61/615,956 filed on Mar. 27, 2012. All applications are hereby incorporated by reference in their entirety.
- The invention relates to a concentrated gel of salicylic acid, and products produced therefrom.
- Salicylic acid, also known as 2-hydroxybenzenecarboxylic acid, is a monohydroxybenzoic acid. Its salts and esters are known as salicylates. Salicylic acid has the formula:
- Salicylic acid is also known for providing pain relief when applied as a liniment, for example
- Salicylic acid is used in many skin-care products. For example, salicylic acid is well known for its use in anti-acne treatments. In addition to the treatment of acne, salicylic acid is also used in products for treatment of psoriasis, calluses, corns, keratosis pilaris, and warts. It works as a keratolytic, bacteriocide and comedolytic agent. Salicylic acid is also used in shampoos for treatment of dandruff and as a chemical exfoliant.
- Salicylic acid can cause burns if applied in high concentrations. Typically, over-the-counter limits are 2% for topical treatments (that remain on the skin) and 3% for cleansers or shampoo (products that are washed off.) Higher concentrations (e.g. up to 40 wt %) may be used for wart removal but should be applied cautiously and only to the wart and not the surrounding skin.
- Salicylic acid is poorly soluble in water. It is therefore difficult to prepare solutions of salicylic acid that remain precipitate-free.
- The present invention is directed to a concentrated salicylic acid gel comprising salicylic acid and a stabilizer compound, wherein the salicylic acid comprises at least 30 wt % of the total weight of the gel.
- The present invention is further directed to a dilute salicylic acid solution comprising the concentrated salicylic acid gel and a solvent wherein the concentration of the salicylic acid in the solution is 25 wt % or less.
- The present invention is further directed to products prepared with the concentrated salicylic acid gel or with dilute solution of the gel in water.
- In one aspect the salicylic acid gel is combined with ingredients to form a body or hand lotion. In another aspect the salicylic acid gel is combined with ingredients to form an anti-dandruff shampoo. In yet another aspect the salicylic acid gel is combined with ingredients to form wart medication. In yet another aspect the salicylic acid gel is combined with ingredients to form an anti-acne medication.
- Aspects of the invention are directed to a concentrated gel of salicylic acid and at least one stabilizer compound selected from nitrogen compounds.
- The concentrated gel comprises at least 30 wt % salicylic acid, for example 30 wt % to 60 wt %, or 40 to 55 wt % salicylic acid, based on total weight of the gel.
- The concentrated gel comprises the stabilizer compound in an amount of 40 to 70 wt %, or 45 to 60 wt %, which is an amount effective to provide stability to the salicylic acid in the gel.
- The concentrated salicylic acid gel is formed by mixing salicylic acid with the stabilizer compound until the salicylic acid is dissolved in the stabilizer compound. No water or solvent such as ethanol is included in the gel. There are only two components that form the gel: the stabilizer compound (complexing agent) and the salicylic acid.
- The mixing of the salicylic acid and the stabilizer compound may be done at room temperature. Alternatively the mixing may occur at an elevated temperature such as up to 50° C. Generally mixing takes about 30 to 120 minutes.
- The concentrated gel may then be stored for future use. Since the gel contains very concentrated salicylic acid, less storage space is required than dilute solutions of salicylic acid.
- The stabilizer compound may be any suitable nitrogen compound that stabilizes the salicylic acid in the concentrated gel. Nitrogen compounds useful to form the highly concentrated salicylic gel include, but not limited to, alkoxylated amides, alkoxylated amines, alkyl-substituted amino acids, alkylamido alkylamines, amides, amine oxides, amines, and betaines. Ideally, a clear product should be produced.
- In one aspect, the nitrogen compound is cocamidopropyl dimethylamine. The cocamidopropyl dimethylamine is particularly suitable for high concentrations of salicylic acid. When diluted in water, the resulting solution is stable and clear.
- The concentrated gel can be diluted to any suitable level for use. Dilution of the salicylic acid gel may occur by the addition of water, a short chain alcohol such as ethanol and isopropanol, or any combination thereof. Upon dilution, the salicylic acid forms a clear, stable solution in the water or alcohols—that is, the salicylic acid does not precipitate out.
- For pH evaluation, 95% water was added to 5% of the gel resulting in a 2% salicylic acid concentration; the maximum allowed for anti-acne products. The same evaluation was run using 92.5% water and 7.5% of the gel (3% active salicylic acid; the maximum allowed for anti-dandruff products) and 40% water and 60% of the gel to evaluate for the wart remover monograph. All of these studies resulted in clear, stable solutions with pH levels between 3 and 4.
- The pH of the dilute system is generally less than 5, such as 2 to 5, 2.5 to 4.5, typically 3 to 4.
- For topical purposes, the dilute system must pass the USP Monograph for a Salicylic Gel which includes an assay for salicylic acid.
- The diluted product may be combined with other suitable ingredients to form the final products such as creams, lotions, make-ups, toners, astringents, skin cleansing compositions, shampoos, and conditioners. These compositions contain about 0.1-40 wt % of salicylic acid. The amount of salicylic acid in the final product depends on the intended purpose of the product.
- C is typically contain about 10-90 wt % water and 10-90 wt % oil. Creams may also contain humectants, emollients, surfactants, emulsifiers, preservatives and fragrances. Creams would generally contain from 0.1 to 5 wt % salicylic acid.
- L4a-t[99s typically contain 20-80 wt % oil and 10-80 wt % water in an emulsion form. In addition, lotions may contain humectants, emollients, surfactants, fragrances, preservatives and so forth. Creams would generally contain from 0.2 to 5 wt % salicylic acidke-ups typically contain about 5-70 wt % oil, 10-95 wt % water, and about 5-40 wt % pigment. In addition, the makeup may contain surfactants, silicones as part of the oil phase, humectants, emollients, preservatives, fragrances, etc. Make-up would generally contain from 0.1 to 3 wt % salicylic acid.
- Anti-dandruff shampoos typically contain 1-40 wt % of a cleansing surfactant and 1090 wt % water. The shampoo may also contain any one of ingredients such as surfactants, colorants, preservatives, fragrance, emulsifiers, viscosity adjusters, and conditioning agents. Anti-dandruff shampoos would generally contain from 0.18 to 3 wt % salicylic acid.
- Hair conditioners typically contain include 10-95 wt % water, 0.5-30 wt % conditioning ingredients such as quaternary ammonium compounds or amphoteric polymers, proteins, etc., and 1-40% surfactants. Hair conditioners may also contain volatile or nonvolatile silicones. Hair conditioners would generally contain from 0.1 to 4 wt % salicylic acid.
- Toners typically contain about 0-85 wt % alcohol, 0.01-5 wt % surfactant, and 0.1-5 wt % humectants, 0.1-85% water.
- The salicylic acid may also be used in ointments, gels, or solutions. Suitable ointments are hydrophilic ointments (USP) or petroleum.
- The amount of salicylic acid present in the final product depends on the product. For example, acne treatment products generally contain 0.5 to 2 wt % salicylic acid, dandruff and seborrheic dermatitis, and psoriasis treatment products generally contain 3 wt % salicylic acid, and wart treatments generally contain up to 40 wt % salicylic acid, typically 5 wt % to 40 wt % or 17 wt % to 25 wt %.
- A 40% salicylic acid was blended with 60% cocamidopropyl dimethylamine. The resulting concentrated gel was slightly viscous, clear, and yellow.
- The concentrated gel was diluted to 2 wt % active salicylic acid in water and separately in ethanol. The resulting solutions were clear and colorless. No precipitate was formed either in water or in ethanol. The pH of the water solution was approximately 3.2.
- Stability tests were then performed on the water solution. The concentrated gel and the diluted 2 wt % active salicylic acid solution were prepared and subjected to accelerated stability protocol which consisted of five freeze/thaw cycles and two weeks in a 50° C. oven. Under both of these conditions there were no significant changes to either sample. The samples that were frozen were obviously solid when removed from the freezer and the 50° C. samples were less viscous. In both cases, when the samples returned to room temperature, they were essentially identical to the control samples. There was no color or viscosity change and no precipitate was formed.
- The gel was also diluted to 25 wt % active salicylic acid in water. The resulting solution was a slightly viscous, yellow, clear solution. No precipitate was formed. A physical accelerated stability test was run on this prototype consisting of samples be held at 50° C. for two weeks and another sample run through five freeze/thaw cycles. Under both of these conditions there were no physical changes to the product include pH, viscosity, color and appearance.
- A lotion was prepared with 5% of the gel of example 1 in 91% water with 4% Egel 305 [Polyacrylamide (&) C12-13 isoparaffin (&) Laureth-7]. The result was a white lotion that would be applicable for an anti-acne product. It underwent the same accelerated stability testing as mentioned above (50° C. for 2 weeks and 5 freeze/thaw cycles); there were no significant physical changes to the product during the stability testing.
- An anti-dandruff shampoo was prepared containing 3 wt % salicylic acid.
-
Percent Water 36.50 Active Cocamidopropyl 7.50 ingredient Diinethylamine (&) Salicylic Acid (Curcylic ® 40) Surfactant PEG-80 Sorbitan 50.00 blend Laurate (&) Cocamidopropyl Betaine (&) Sodium Trideceth Sulfate (&) Glycerin (&) Disodium Lauroamphodiacetate (&) PEG-150 Distearate (&) Sodium Laureth-13 Carboxylate (Sulfochem ™ B-NBB) Thickener PEG-120 Methyl 5.00 Glucose Trioleate (&) Propylene Glycol (&) Water (Glucamate ™ LT) Preservative Propylene Glycol (&) 1.00 Diazolidinyl Urea (&) Methylparaben (&) Propylparaben (Nipaguard PDU) Citric Acid qs to pH 4 100.00% - In an appropriate container, water, and Curcylic®40 were mixed until uniform. Sulfochem B-NBB, Glucamate LT and Nipaguard PDU were added and mixed until homogenous. Then citric acid was added, with continued mixing, until the batch reached pH of approximately 4.0. Viscosity: >1300 cp. Stability: Passed 2 weeks 50° C.; 5 Freeze/Thaw cycles.
- While the invention has been described with respect to specific examples including presently preferred modes of carrying out the invention, those skilled in the art will appreciate that there are numerous variations and permutations of the above described systems and techniques that fall within the spirit and scope of the invention as set forth in the appended claims.
Claims (20)
1. A salicylic acid gel comprising salicylic acid and a stabilizing amount of at least one nitrogen compound, wherein the salicylic acid comprises at least 1 wt % of the total weight of the gel.
2. The salicylic acid gel of claim 1 including at least 20 wt % salicylic acid based on the total wright of the gel.
3. The salicylic acid gel of claim 2 including at least 30 wt % salicylic acid based on the total weight of the gel.
4. The salicylic acid gel of claim 3 including 40 to 55 wt % salicylic acid based on the total weight of the gel.
5. The salicylic acid gel of claim 1 including at least 40 wt % of the nitrogen compound based on the total weight of the gel.
6. The salicylic acid gel according to claim 1 in which the nitrogen compound is selected from the group consisting of alkoxylated amides, alkoxylated amines, alkyl-substituted amino acids, alkylamido alkylamines, amides, amine oxides, amines, and betaines.
7. The salicylic acid gel of claim 6 in which the nitrogen compound is cocamidopropyl dimethylamine.
8. The salicylic acid gel according to claim 1 in which no solvent is present in the gel.
9. The salicylic acid gel according to claim 8 in which the nitrogen compound is selected from the group consisting of alkoxylated amides, alkoxylated amines, alkyl-substituted amino acids, alkylamido alkylamines, amides, amine oxides, amines, and betaines.
10. The salicylic acid gel according to claim 9 in which the nitrogen compound is cocamidopropyl dimethylamine.
11. The salicylic acid gel of claim 1 in the form of a solvent and including a solvent.
12. The salicylic acid solution of claim 11 including at least 0.5 wt % salicylic acid based on total weight of the solution.
13. The salicylic acid solution of claim 11 in which the pH of the solution is 2 to 5 or 3 to 4.
14. The salicylic acid solution of claim 11 in which the solvent is water, ethanol, or isopropylalcohol.
15. An acne treatment product comprising the salicylic acid gel according to claim 1 and a solvent in which the concentration of the salicylic acid is 0.5 to 2 wt % based on the total weight of the acne treatment product.
16. A wart treatment product comprising the salicylic acid gel according to claim 1 , and a solvent in which the concentration of the salicylic acid 5 to 40 wt % or 17 to 25 wt % based on the total weight of the wart treatment product.
17. A lotion comprising the salicylic acid gel according to claim 1 and a solvent in which the concentration of the salicylic acid is 0.2 to 5 wt % based on the total weight of the lotion.
18. An anti-dandruff shampoo comprising the salicylic acid gel according to claim 1 and a solvent in which the concentration of the salicylic acid of 1.8 to 3 wt % based on the total weight of the shampoo.
19. A method of making a salicylic acid solution comprising combining the salicylic acid gel according to claim 1 with a solvent and mixing.
20. A method of making a skin care product having a multiplicity of ingredients comprising combining with mixing the salicylic acid gel according to claim 1 , a solvent, and the ingredients.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/688,560 US20170354734A1 (en) | 2012-03-27 | 2017-08-28 | Salicylic acid gel |
US16/832,171 US20200316206A1 (en) | 2012-03-27 | 2020-03-27 | Salicylic acid gel |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261615956P | 2012-03-27 | 2012-03-27 | |
US13/789,780 US8828979B2 (en) | 2012-03-27 | 2013-03-08 | Salicylic acid gel |
US14/454,886 US20140349978A1 (en) | 2012-03-27 | 2014-08-08 | Salicylic Acid Gel |
US15/688,560 US20170354734A1 (en) | 2012-03-27 | 2017-08-28 | Salicylic acid gel |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/454,886 Continuation US20140349978A1 (en) | 2012-03-27 | 2014-08-08 | Salicylic Acid Gel |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/832,171 Continuation US20200316206A1 (en) | 2012-03-27 | 2020-03-27 | Salicylic acid gel |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170354734A1 true US20170354734A1 (en) | 2017-12-14 |
Family
ID=49235845
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/789,780 Expired - Fee Related US8828979B2 (en) | 2012-03-27 | 2013-03-08 | Salicylic acid gel |
US14/454,886 Abandoned US20140349978A1 (en) | 2012-03-27 | 2014-08-08 | Salicylic Acid Gel |
US15/688,560 Abandoned US20170354734A1 (en) | 2012-03-27 | 2017-08-28 | Salicylic acid gel |
US16/832,171 Pending US20200316206A1 (en) | 2012-03-27 | 2020-03-27 | Salicylic acid gel |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/789,780 Expired - Fee Related US8828979B2 (en) | 2012-03-27 | 2013-03-08 | Salicylic acid gel |
US14/454,886 Abandoned US20140349978A1 (en) | 2012-03-27 | 2014-08-08 | Salicylic Acid Gel |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/832,171 Pending US20200316206A1 (en) | 2012-03-27 | 2020-03-27 | Salicylic acid gel |
Country Status (3)
Country | Link |
---|---|
US (4) | US8828979B2 (en) |
MX (1) | MX2015011497A (en) |
WO (1) | WO2014137395A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2708250C1 (en) * | 2019-03-15 | 2019-12-05 | Федеральное государственное бюджетное учреждение науки Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (ИНХС РАН) | Method of producing chemical peeling gel |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018200646A1 (en) * | 2017-04-26 | 2018-11-01 | The Procter & Gamble Company | Compositions with a thickening polymer |
KR102041389B1 (en) | 2017-12-12 | 2019-11-27 | (주)프론트바이오 | N-(9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-yl)-2-hydroxybenzamide and 2-((9,13b-dihydro-1H-dibenzo[c,f]imidazo[1,5-a]azepin-3-yl) carbamoyl)phenyl acetate compound, and method for producing the same, and composition for the anti-inflammatory and analgesia comprising the same |
CN114569494B (en) * | 2022-04-29 | 2022-08-09 | 广东一芙化妆品有限公司 | Composition for removing makeup, preparation method, packaging method and using method thereof, and makeup removing gel |
WO2024087150A1 (en) * | 2022-10-28 | 2024-05-02 | L'oreal | Composition for conditioning the hair |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3637508A (en) | 1970-03-06 | 1972-01-25 | William B Willsey | Process and composition for dissolving copper oxide |
US4067974A (en) | 1976-01-21 | 1978-01-10 | The Purdue Frederick Company | Stabilized solid form choline salicylate compositions |
US4954487A (en) | 1979-01-08 | 1990-09-04 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions |
US4505896A (en) | 1979-04-19 | 1985-03-19 | Elorac, Ltd. | Method of treating acne vulgaris and composition |
US4338311A (en) | 1980-10-27 | 1982-07-06 | Riker Laboratories, Inc. | Hydrophilic choline salicylate formulation |
US4588590A (en) | 1981-12-21 | 1986-05-13 | Jaye-Boern Laboratories, Inc. | Method of treating keratosis and compositions useful therefor |
IL68965A (en) | 1983-06-13 | 1987-02-27 | Rafa Labor Ltd | Topical pharmaceutical preparation comprising acetylsalicylic acid for the treatment of dermatological disorders |
FR2581542B1 (en) | 1985-05-07 | 1988-02-19 | Oreal | TOPICAL COMPOSITIONS FOR THE TREATMENT OF SKIN BASED ON SALICYLIC ACID DERIVATIVES |
FI930459A (en) * | 1992-03-27 | 1993-09-28 | Curtis Helene Ind Inc | SCHAMPOKOMPOSITIONER OCH SUSPENDERINGSMEDEL FOER DESSA |
FR2714831B1 (en) | 1994-01-10 | 1996-02-02 | Oreal | Cosmetic and / or dermatological composition containing salicylic acid derivatives and method for solubilizing these derivatives. |
DE4420727A1 (en) | 1994-06-15 | 1995-12-21 | Rovi Gmbh | Skin-friendly aqueous liposome dispersions containing alpha-hydroxycarboxylic acids and / or alpha-hydroxyketo acids in their salt form |
US5449519C1 (en) | 1994-08-09 | 2001-05-01 | Revlon Consumer Prod Corp | Cosmetic compositions having keratolytic and anti-acne activity |
US5505949A (en) | 1994-10-13 | 1996-04-09 | Benitez; Juan E. | Topical treatment for acne |
FR2743813B1 (en) | 1996-01-23 | 1998-02-20 | Oreal | STABLE GEL COMPOSITION WITH HIGH ELECTROLYTE CONTENT |
EP0881897A4 (en) | 1996-02-08 | 2000-04-19 | Douglas E Kligman | Composition and method for effecting superficial chemical skin peels |
US20040102358A1 (en) | 1997-05-19 | 2004-05-27 | Scivoletto Rosemarie | Composition for treating skin conditions |
FR2780888B1 (en) | 1998-07-09 | 2000-10-13 | Benac | CLEANSING AND TREATMENT LOTION FOR COMEDON TREATMENT |
US6120756A (en) | 1998-08-19 | 2000-09-19 | Philip I. Markowitz | Topical anionic salicylate for disorders of the skin |
US6200964B1 (en) | 1999-05-28 | 2001-03-13 | Neutrogena Corporation | Silicone gel containing salicylic acid |
US6177413B1 (en) | 2000-03-03 | 2001-01-23 | Natalie Blahut | Stabilized aspirin compositions and method of preparation for oral and topical use |
US8492366B2 (en) | 2002-10-07 | 2013-07-23 | Societe L'oreal S.A. | Enhancedly-solubilized beta-hydroxy acids and higher potency skin peels formulated therefrom |
DE60238283D1 (en) * | 2002-11-25 | 2010-12-23 | Jallal Messadek | Betaine and salicylic acid compositions |
CA2729967C (en) | 2002-12-13 | 2018-01-16 | Schering-Plough Healthcare Products, Inc. | Use of a transdermal or transmucosal ingredient delivery device |
US20040161392A1 (en) | 2003-02-19 | 2004-08-19 | L'oreal S.A. | Skin peeling composition and method |
US20040248858A1 (en) | 2003-06-09 | 2004-12-09 | Parghi Kaumil H. | Cure for cancer |
US20050002996A1 (en) | 2003-07-02 | 2005-01-06 | Milan Sojka | Sustained release compositions and controlled delivery method |
US9089494B2 (en) | 2004-09-14 | 2015-07-28 | Coty S.A. | Ultra-violet inhibition system |
US20060067958A1 (en) | 2004-09-24 | 2006-03-30 | Unilab Pharmatech, Ltd. | Pharmaceutical topical gel compositions |
ES2350452T3 (en) | 2004-11-22 | 2011-01-24 | Venus Remedies Limited | NON-WATERPROOF LIQUID ACECLOFENAC PARENTERAL FORMULATION. |
ATE493177T1 (en) * | 2005-03-04 | 2011-01-15 | Procter & Gamble | WASHABLE OR WIPABLE SKIN CLEANING COMPOSITIONS |
US20070042007A1 (en) | 2005-08-19 | 2007-02-22 | Joseph Schwarz | Topical composition for delivery of salicylate esters |
EP2100601B1 (en) | 2005-10-24 | 2012-06-27 | Precision Dermatology, Inc. | Topical pharmaceutical foam composition |
FR2894142B1 (en) * | 2005-12-05 | 2009-06-12 | Oreal | USE OF THE TYROSINE-ARGININE DIPEPTIDE AND NIACIMANIDE ASSOCIATION AS A P-SUBSTANCE ANAGONIST |
US8685471B2 (en) | 2006-07-17 | 2014-04-01 | Tyratech, Inc. | Compositions and methods for controlling insects |
US8337869B2 (en) | 2007-08-07 | 2012-12-25 | Gross Robert L | Analgesic cream |
JP2011522831A (en) | 2008-06-05 | 2011-08-04 | リチャード イー. デビッドソン | Acne treatment composition containing nanosilver and use thereof |
US8409600B2 (en) | 2009-01-23 | 2013-04-02 | J&E Solutions, Llc | Methods for prevention and/or treatment of capsular contracture |
US20110160166A1 (en) | 2009-12-31 | 2011-06-30 | Karen Hohenstein | Therapeutic composition for the treatment and prevention of athlete's foot and fungal infections of the nail and surrounding tissues |
-
2013
- 2013-03-08 US US13/789,780 patent/US8828979B2/en not_active Expired - Fee Related
- 2013-09-30 WO PCT/US2013/062561 patent/WO2014137395A1/en active Application Filing
- 2013-09-30 MX MX2015011497A patent/MX2015011497A/en active IP Right Grant
-
2014
- 2014-08-08 US US14/454,886 patent/US20140349978A1/en not_active Abandoned
-
2017
- 2017-08-28 US US15/688,560 patent/US20170354734A1/en not_active Abandoned
-
2020
- 2020-03-27 US US16/832,171 patent/US20200316206A1/en active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2708250C1 (en) * | 2019-03-15 | 2019-12-05 | Федеральное государственное бюджетное учреждение науки Ордена Трудового Красного Знамени Институт нефтехимического синтеза им. А.В. Топчиева Российской академии наук (ИНХС РАН) | Method of producing chemical peeling gel |
Also Published As
Publication number | Publication date |
---|---|
US20200316206A1 (en) | 2020-10-08 |
WO2014137395A1 (en) | 2014-09-12 |
MX2015011497A (en) | 2016-06-21 |
US8828979B2 (en) | 2014-09-09 |
US20140349978A1 (en) | 2014-11-27 |
US20130261091A1 (en) | 2013-10-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200316206A1 (en) | Salicylic acid gel | |
KR100690469B1 (en) | Gelled Aqueous Cosmetic Compositions | |
ES2327901T3 (en) | METHOD FOR PREPARING DISPERSIONS CONTAINING PHYSIOLOGICALLY ACTIVE INGREDIENTS AT HIGH PRESSURE / HIGH SHEAR. | |
JP5008573B2 (en) | Preservative | |
US20110152384A1 (en) | Mild leave-on skin care compositions | |
KR20100075475A (en) | Pharmaceutical composition | |
WO2009129627A1 (en) | Novel resveratrol compositions | |
KR20110121702A (en) | Method of dissolving antifungal agent, and compositions with a high concentration of antifungal agent, suitable for application to the nail | |
US9018177B2 (en) | Cosmetic compositions for increasing bioavailability of the active compounds baicalin and/or vitamin C | |
KR20100131972A (en) | Improving the appearance of nails | |
EP2964189B1 (en) | Salicylic acid gel | |
US20140323445A1 (en) | Salicylic Acid Gel | |
KR101937072B1 (en) | External agent for treating hyperhidrosis | |
KR20180070706A (en) | New formulation | |
JP4915713B2 (en) | Antibacterial composition | |
JP5353168B2 (en) | Minoxidil-containing external preparation | |
WO2022259901A1 (en) | Hyaluronate skin-penetrating cosmetic | |
CN107233222A (en) | A kind of composition with liquid crystal structure and its application in cosmetics | |
JP6221536B2 (en) | Composition for external use | |
US20210338540A1 (en) | Salicylic acid gel | |
US20170281509A1 (en) | Compositions and methods for mitigating skin irritation | |
BR112015001018B1 (en) | USE OF A CREAM THAT PROTECTS AGAINST THE EFFECTS OF AGGRESSIVE CHEMICAL AGENTS IN CONTACT WITH THE SKIN | |
JP2021123586A (en) | Pharmaceutical composition for external use | |
JP2021123585A (en) | Pharmaceutical preparation for external use | |
JPH07304690A (en) | Keratin solubilizer, percutaneous absorption accelerator and external skin preparation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |